About
    Novo Group
    Leadership
    Responsibility
    Novo Nordisk Foundation
  • About
  • Investments
    Areas
    Life Science
    Seed InvestmentsVenture InvestmentsGrowth InvestmentsPrincipal InvestmentsPlanetary Health Investments
    Capital Investments
    Strategy
    Regions
    North AmericaEuropeAsia
    Portfolio
  • Investments
  • People
    Careers
    Open positions
  • People & Careers
  • News & Reports
    Facts & Figures
    Media Library
    Contact Public Relations
  • News & Reports

Francis Cuss

Department

Board of Directors

Position

Board Member

Member of the Board since 2017.

Francis Cuss was born in 1954 and is a dual national of both the United Kingdom and the United States. He received a BA in Natural Sciences, MB, BChir and MA from Cambridge University. He is a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine. Francis Cuss began his career in clinical medicine and research in the United Kingdom.

Francis Cuss has over 35 years of clinical experience across the pharmaceutical industry. In 1986 he started at GlaxoSmithKline plc (then Glaxo Inc.), UK and United States, as a Director in Pulmonary Clinical Research. From 1989, Francis Cuss worked at the Schering-Plough Research Institute where he held several positions in Discovery and Development, eventually becoming Senior Vice President of Early Clinical Research & Experimental Medicine. Francis Cuss joined Bristol-Myers Squibb Research & Development in 2003, first working as Senior Vice President of Discovery and later as Senior Vice President for all of Research and Early Development. In 2010, he joined the company’s senior management team. In 2013, he was appointed Executive Vice President, Chief Scientific Officer and Head of Research & Development at Bristol-Myers Squibb Company, retiring in 2017.

Other Board Positions and Management Duties:

  • Chair and Board Member, the Board of Trustees for Montclair State University in New Jersey, United States

  • Board Member, Rubius Therapeutics Inc., United States

  • Board Member, Glympse Bio, United States

Investing to benefit people and the planet

Novo Holdings A/S

Tuborg Havnevej 19

2900 Hellerup Denmark

+45 3527 6500

Email: Info@novoholdings.dk

CVR# 24257630

Media Relations

Christian Mostrup Scheel

Head of Public Relations

Email: novoholdingsmedia@novo.dk

+45 3067 4805

Novo Holdings US Inc.*

Boston:

200 Clarendon Street, Floor 45

Boston, MA 02116 USA

San Francisco:

One Market Plaza, Floor 17 of the Steuart Tower

San Francisco, CA 94105 USA

+1 (415) 552-6686

Email: Info@novoholdings.dk

Novo Holdings Equity Asia Pte. Ltd.*

#40-01, 6 Battery Road

Singapore 049909

Email: Info@novoholdings.dk

Novo Holdings (UK office)

16 Berkeley Street

London W1J 8DZ

Email: Info@novoholdings.dk

Privacy noticeCode of ConductWhistleblowerArticles of association Policy on data ethicsElectronic invoicingDiversity policy

*Novo Ventures (US) Inc., Novo Holdings US Inc., comprising Novo Growth and Principal Investments, and Novo Holdings Equity Asia Pte. Ltd. are separate legal entities that provide certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.

Follow us